Etoposide compared with the combination of vincristine, doxorubicin, and cyclophosphamide in the treatment of small cell lung cancer

McIllmurray, M B; Bibby, R J; Taylor, B E; Ormerod, L P; Edge, J R; Wolstenholme, R J; Willey, R F; O'Reilly, J F; Horsfield, N; Johnson, C E
March 1989
Thorax;Mar1989, Vol. 44 Issue 3, p215
Academic Journal
No abstract available.


Related Articles

  • NICE recommendations: topotecan in, bevacizumab out.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p2 

    The article reports that Great Britain National Institute for Clinical Excellence (NICE) recommended the use of topotecan as a second-line treatment for relapsed small-cell lung cancer. NICE suggested the use of oral topotecan as an option for patients who cannot take combined cyclophosphamide,...

  • Randomized Phase III Trial of Paclitaxel, Etoposide, and Carboplatin Versus Carboplatin, Etoposide, and Vincristine in Patients With Small-Cell Lung Cancer. Reck, Martin; von Pawel, Joachim; Macha, Hans-Nicolas; Kaukel, Eckhard; Deppermann, Karl-Matthias; Bonnet, Reiner; Ulm, Kurt; Hessler, Sybill; Gatzemeier, Ulrich // JNCI: Journal of the National Cancer Institute;8/06/2003, Vol. 95 Issue 15, p1118 

    Cites the results of a randomized phase III trial from 1998 to 1999 comparing the efficacy of carboplatin, etoposide and paclitaxel and of vincristine, etoposide and carboplatin in treating small-cell lung cancer. Patient eligibility; Treatment protocol; Treatment evaluations and statistical...

  • Twenty-Seven Years of Phase III Trials for Patients with Extensive Disease Small-Cell Lung Cancer: Disappointing Results.  // PLoS ONE;2009, Vol. 4 Issue 11, p1 

    The article discusses a study in which literature search has been done to determine whether patient outcomes have improved in the treatment of extensive disease and Small-cell lung cancer (ED-SCLC). It has been informed Phase III randomized controlled trials that were compared first-line,...

  • Re: Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized... Pfeiffer, Per; Rytter, Carsten; Madsen, Ebbe Lindegaard; Moeholt, Kirsten; Hansen, Olfred; Bentzen, Soren; Palshof, Torben; Rose, Carsten // JNCI: Journal of the National Cancer Institute;12/17/97, Vol. 89 Issue 24, p1892 

    Investigates whether single-agent, daily, oral etoposide is an effective, palliative therapy for advanced small-cell lung cancer as compared with combination therapy. Bioavailability of oral etoposide; Comparison of tumor response to oral etoposide and combination therapy in patients with...

  • Successful treatment of BALT lymphoma with combined chemotherapy. Ali, R.; Özakalemkaş, F.; Özçelik, T.; Özkocaman, V.; Ozan, Ü.; Tunali, A.; Filiz, G.; Gözü, O.; Ozkalemkaş, F; Ozçelik, T; Ozkocaman, V; Ozan, U; Gözü, O // Thorax;Apr2003, Vol. 58 Issue 4, p368 

    Presents a letter to the editor of the journal 'Thorax,' describing the case of a 30-year-old man with low grade B cell bronchus-associated lymphoid tissue lymphoma who presented with a bulky mass in the lungs. Symptoms; Clinical pathology; Treatment with cyclophosphamide, doxorubicin,...

  • Effect of Retinoic Acid and Chemotherapeutic Agents on Untrastructural Localization of Myc-N in Neuroblastoma. Aktas, Safiye; Altun, Zekiye; Ozogul, Candan; Olgun, Nur // Journal of Neurological Sciences;2012, Vol. 29 Issue 3, p588 

    The effect mechanism of pharmacological agents used in neuroblastoma treatment on myc-N expression is still unclear. Myc-N amplification does not change with any agent. The aim of this study is to investigate the effect of chemotherapeutic agents and retinoic acid on ultra structural...

  • Sister Mary Joseph's Nodule. Albano, Edythe A.; Kanter, Julie // New England Journal of Medicine;5/5/2005, Vol. 352 Issue 18, p1913 

    Presents a clinical medicine image of a girl presented with a one-month history of decreased appetite, vomiting and weight loss, and diagnoses with metastatic cancer of the umbilicus, known as Sister Mary Joseph's nodule. Report that the girl had a tumor protruding through the umbilicus;...

  • FDG–PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive value. Markova, J.; Kobe, C.; Skopalova, M.; Klaskova, K.; Dedeckova, K.; Plütschow, A.; Eich, H. T.; Dietlein, M.; Engert, A.; Kozak, T. // Annals of Oncology;Jul2009, Vol. 20 Issue 7, p1270 

    Background: As positron emission tomography (PET) seems to be a powerful prognostic marker in the treatment of Hodgkin's lymphoma (HL), we analysed the prognostic value of PET after four cycles of combination therapy with bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine,...

  • Tacrolimus.  // Reactions Weekly;9/9/2006, Issue 1118, p17 

    The article presents a case report of a 47-year-old male liver transplant recipient who developed adult T-cell leukaemia (ATL) during immunosuppressive treatment with tacrolimus. The patient was treated with three cycles of combined chemotherapy with cyclophosphamide, doxorubicin, prednisolone,...

  • Initial Chemotherapeutic Doses and Survival in Patients with Limited Small-Cell Lung Cancer. Arriagada, Rodrigo; Le Chevalier, Thierry; Pignon, Jean-Pierre; Riviere, Alain; Monnet, Isabelle; Tuchais, Claude; Tarayre, Michele; Chomy, Pierre; Ruffie, Pierre // New England Journal of Medicine;12/16/93, Vol. 329 Issue 25, p1848 

    Background: Moderate increases in the initial doses of certain chemotherapeutic drugs, such as cisplatin and cyclophosphamide, may prolong overall survival in patients with limited small-cell lung cancer. Methods: We conducted a prospective study of 105 patients with limited small-cell lung...


Read the Article


Sign out of this library

Other Topics